In clinical trials, Navitoclax has produced good therapeutic outcomes for both patients with lymphoid malignancies13 and with CLL,14 but it caused thrombocytopenia, which is a severe undesired side effect that is frequently observed in Bcl‐xL. The gene discussed is BCL2L1; the disease is B-cell chronic lymphocytic leukemia.